论文部分内容阅读
近20年来,随着新技术的应用,灭活疫苗和减毒活疫苗新品种不断出现,还有亚单位疫苗、DNA重组疫苗、人工合成多肽疫苗等新型疫苗相继问世。但是,疫苗接种的基本原理并没有取得突破,仍然要使用外源性抗原物质刺激机体,使机体主动建立对该抗原的特异性免疫应答。因此,在这一理论指导下,为了大规模地对人群进行有效的计划免疫,必需生产和供应大量有效的抗原。目前,在一些严重威胁人类的传染病中,有些病原体的体外培养尚未成功,有的在抗原纯化上还存在着技术上、经济上的困难,这些都限制了大量有效抗原的供应。采用DNA重组技术可克服有效抗原的来源问题,但
In the recent 20 years, with the application of new technologies, new inactivated and attenuated live vaccines have emerged, and new vaccines such as subunit vaccines, recombinant DNA vaccines and synthetic peptide vaccines have been released one after another. However, the basic principles of vaccination and did not make a breakthrough, still use exogenous antigen substances to stimulate the body, so that the body take the initiative to establish a specific immune response to the antigen. Therefore, under the guidance of this theory, it is necessary to produce and supply a large number of effective antigens in order to carry out effective planned immunization on a large scale. At present, in some serious infectious diseases that threaten human beings, in vitro culture of some pathogens has not been successful yet, and there are still technical and economic difficulties in antigen purification, which limit the supply of a large number of effective antigens. Using DNA recombination techniques can overcome the source of effective antigens, however